AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05405829 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education
Description: theoretical-practical hygienic-dietary training, with visual support and work materials where three specific interventions are explained: textures for solids and liquids, safety postures to reduce the risk of bronchial aspiration, and oral hygiene. In addition, tools are offered to caregivers so that they can identify situations of anxiety and overload, as well as guidelines for social support.
Study NCT04626622 — intervention group
Intervention type: DRUG
Intervention: Kagocel
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study NCT04626622 — intervention group
Intervention type: DRUG
Intervention: No one
Description: Investigators don't prescribe any antiviral drugs in frame of routine clinical practice
Study NCT00903084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir Disoproxil Fumarate
Description: 300-mg tablet
Study NCT00316875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: 1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
Study NCT00316875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil
Description: Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
Study NCT02505984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Study participants will be randomized to a placebo or drug group.
Study NCT02505984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to a placebo or drug group.
Study NCT02333227 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Description: This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
Study NCT04108507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior branch block of spinal nerve
Description: posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
Study NCT01042262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% Oxygen at a flow of 2 L/min
Study NCT01042262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No oxygen flow
Study NCT01620125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lactobacillus reuteri DSM 17938
Description: Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
Study NCT02279511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADENOSINE TRIPHOSPHATE
Description: Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
Study NCT02279511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Infusion of 500 mL of saline solution. (IV)
Study NCT01882361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable naltrexone
Description: Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
Study NCT01254305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine, Sertraline, Citalopram or Fluoxetine.
Description: Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
Study NCT01882361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: this placebo has no specific pharmacological activity
Study NCT00609960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam
Study NCT01188135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice messaging or Interactive voice messaging + psycho ed materials
Description: Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
Study NCT01254305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily dosing
Study NCT00433576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Given orally
Study NCT00433576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00433576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adenosine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regadenoson
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 13N-ammonia
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13N-ammonia
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 82Rubidium
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT03236311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 82Rubidium
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study NCT01723397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasaleze Spray
Description: Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
Study NCT01723397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: Subjects are treated with placebo nasal spray then challenged with allergen
Study NCT01723397 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
Study NCT01723397 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergen
Description: Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
Study NCT01416129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care socket
Description: Amputees' preferred socket.
Study NCT01416129 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic brimless socket
Description: Study socket
Study NCT04074486 — intervention group
Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP-O
Description: BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
Study NCT04074486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT5
Description: Sports Concussion Assessment Tool 5
Study NCT04074486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Near Point Convergence
Description: Manual ocular function measurement conducted only if electronic version on device fails
Study NCT04550273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic treadmill exercise
Description: The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
Study NCT01639183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotating-oscillating Power Toothbrush
Description: A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
Study NCT01639183 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
Study NCT03280212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Tranexamic Acid 500mg oral tablets.
Study NCT03550690 — intervention group
Intervention type: DEVICE
Intervention: Large Volume Paracentesis
Description: Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
Study NCT03550690 — intervention group
Intervention type: DEVICE
Intervention: Rocket Indwelling Pleural Catheter
Description: A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
Study NCT02341612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single exposure at 5°C in CWI
Description: The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
Study NCT02341612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single exposure at 15°C in CWI
Description: The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
Study NCT02341612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multiple exposures at 10°C in CWI
Description: The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
Study NCT02341612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryotherapy (WBC)
Description: The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
Study NCT02341612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive recovery
Description: The control group was exposed to treatment after the EIMD protocol.
Study NCT01929070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007
Study NCT02079194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist monotherapy
Study NCT02079194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin plus P2Y12 antagonist
Study NCT00059306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
Study NCT00059306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
Study NCT00059306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Target of Blood Pressure
Description: Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
Study NCT00059306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT01929070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarco and Crestor
Study NCT00807664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ag
Description: Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
Study NCT00807664 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biatain
Description: A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
Study NCT04519944 — intervention group
Intervention type: DRUG
Intervention: Edoxaban
Description: This is an observational, prospective study; no treatment will be administered.
Study NCT01372345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study NCT01372345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study NCT01299025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training using Nintendo Wii Fit
Description: Training 2 times per week, 30 minutes, for 6 weeks.
Study NCT01624194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: 24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.
Study NCT01624194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
Study NCT00836940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Study NCT00836940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Study NCT02731534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
Study NCT02731534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharated Ferric Oxide
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
Study NCT02900443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study NCT02900443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study NCT00316186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
Study NCT00316186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
Study NCT03084471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
Study NCT03084471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab) + Tremelimumab
Description: Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood.
Study NCT01123694 — intervention group
Intervention type: OTHER
Intervention: Survey Study
Description: Survey regarding quality of life
Study NCT01459185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
Study NCT01498120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day
Study NCT04032782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15136
Description: 10 mg/mL as protein in prefilled syringes
Study NCT04032782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HM15136
Description: Placebo in prefilled syringes
Study NCT01341730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: 20 mg QD for 3 months
Study NCT01341730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + Pioglitazone 30 mg
Description: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
Study NCT03379467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: A text message sent as a reminder for immunization on the registered phone number
Study NCT03379467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Reminder
Description: A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
Study NCT02491905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL tablet
Study NCT02491905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02130856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal kit
Description: Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker.
Study NCT02601560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
Study NCT03881774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
Study NCT01027949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
Study NCT02601560 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
Study NCT02601560 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
Study NCT00872092 — intervention group
Intervention type: OTHER
Intervention: Stable-isotope labeled lactose ureide breath test
Description: 2 g 13C-labeled lactose ureide orally
Study NCT02431494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue light phototherapy
Description: Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
Study NCT02431494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microcurrent therapy
Description: Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.